Ovace

Quick links to important sections

Ovace

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovace

Ovace is a prescription-only topical medicine classified as a sulfonamide antibiotic and an antibacterial agent. Its medicinal activity is derived from its single active ingredient, Sulfacetamide (specifically Sodium Sulfacetamide).

Property Description
Active ingredient Sulfacetamide (Sodium Sulfacetamide)
Form Cream, Lotion, Shampoo, Wash (Cleansing Gel), Foam
Pharmacological class Sulfonamide Antibiotic / Antibacterial Agent
Common use Control of bacterial proliferation on skin and scalp
Origin Synthetic compound

This medicine is a synthetic compound, meaning its structure is chemically manufactured. Sulfacetamide belongs to the sulfonamide pharmacological group, which are recognized for their targeted efficacy against susceptible microorganisms. Sulfacetamide is effective in topical preparations to help manage bacterial overgrowth on the skin.


How Ovace Functions: Principle of Bacterial Growth Control

Ovace functions by employing a bacteriostatic mechanism, which means it works by inhibiting the growth and multiplication of susceptible bacteria present on the skin and scalp. The fundamental principle of its action involves interrupting a critical biological pathway within the bacteria, thus preventing their reproduction and spread.

This targeted action translates to the general purpose of the medicine: to help control bacterial proliferation on the surface of the skin. By reducing the overall bacterial load, Ovace is clinically recognized for mitigating the bacterial contribution to dermatological conditions, such as those that manifest primarily on the scalp or face.

Regulatory References

  1. Sulfacetamide Sodium and Sulfur Cream Drug Label (DailyMed/NIH)
  2. U.S. National Library of Medicine (NLM) official website
  3. Sulfacetamide Topical MedlinePlus Drug Information

What side effects are possible with Ovace?

Possible Side Effects and Safety Information

The safety profile of Ovace (sodium sulfacetamide) is primarily characterized by adverse reactions at the application site, reflecting its local action as a topical sulfonamide antibiotic. The most frequently documented adverse reactions are classified as infrequent (uncommon) and involve the Skin and Subcutaneous Tissue Disorders system-organ class.

Commonly reported effects include local irritation, stinging, burning, redness (erythema), and itching (pruritus). These reactions are typically localized and are the expected primary effects observed during treatment.

Serious Adverse Reactions and Class Warnings

Although rare with topical use, regulatory documents warn of the potential for serious systemic reactions associated with the sulfonamide drug class. These are crucial safety considerations and include severe, life-threatening conditions such as Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), and serious blood dyscrasias (e.g., agranulocytosis). Fatalities, though rare, have been associated with these systemic toxic reactions, which indicate hypersensitivity.

Population-Specific Safety and Limitations

Ovace is contraindicated in individuals with a known or suspected hypersensitivity to sulfonamides or sulfites. Caution is advised when the medication is applied to denuded or abraded skin due to the potential for increased systemic absorption. Furthermore, prolonged use carries a safety constraint: the potential for the overgrowth of non-susceptible organisms, including fungi, a risk common to many antibiotic preparations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Manifestations and Scope

Regulatory documentation for topical sodium sulfacetamide identifies specific clinical manifestations associated with overdosage, primarily following accidental ingestion. Acute, documented symptoms include nausea and vomiting. The profile highlights a significant risk of severe renal complications, particularly associated with large oral overdosage. These outcomes, stemming from the precipitation of sulfa crystals in the renal tubules and urinary tract, are characterized by crystalluria and hematuria, and may potentially lead to renal shutdown. This serious physiological risk is particularly pertinent for patients with pre-existing kidney disease, who face an elevated risk of severe outcomes.


Required Emergency Action

Official regulatory statements mandate that emergency treatment must be started immediately upon the recognition of a suspected overdosage. When accidental ingestion has occurred, the regulator requires contacting a Poison Control Center immediately. The general instruction for managing overdosage is to contact a local Poison Control Center or a doctor for guidance. The official prescribing information does not list a specific antidote, meaning treatment focuses on providing supportive and symptomatic care to manage the clinical manifestations and mitigate the risk of crystal precipitation.

Therapeutic Uses of Ovace

Quick Facts

  • Relieves symptoms associated with seborrheic dermatitis.
  • Helps manage dandruff and scaling of the scalp.
  • Supports recovery from specific secondary bacterial skin infections.

What Ovace Treats: Main Uses and Benefits

Ovace (sodium sulfacetamide) is a prescription topical medication used to address certain skin and scalp conditions. The primary therapeutic application is to help manage the symptoms of seborrheic dermatitis. This condition involves scaling and discomfort on the skin and scalp.

The medication also contributes to the control of dandruff, specifically the scaling that may occur due to seborrhea sicca.

Furthermore, Ovace provides treatment for secondary bacterial infections of the skin that are caused by microorganisms susceptible to its active component. These infections may be associated with the primary dermatoses. Utilizing Ovace, when indicated by a healthcare professional, supports the resolution of these infections on the skin and scalp. This information reflects the established therapeutic use of the product family.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Ovace

This section outlines the population eligibility rules and prohibitions for Ovace (topical sodium sulfacetamide) as documented in official government labeling.

Category Regulatory Status
Absolute Contraindication Patients with known hypersensitivity to sulfonamides or any component of the preparation.
Condition Restriction Patients with kidney disease are contraindicated from use.
Pediatric Use Safety and effectiveness have not been established for children under 12 years of age.
Pregnancy Classified as Pregnancy Category C. Use is restricted to cases where it is clearly needed.
Lactation Caution is advised for nursing mothers due to the potential for systemic sulfonamides to affect infants, although topical absorption levels are unknown.

Eligibility is defined by mandatory exclusions based on allergy and comorbidity, primarily sulfonamide hypersensitivity and pre-existing kidney disease. The medicine's use is established for adults and adolescents ge 12 years. Conditional use applies to pregnant women and nursing mothers as specified in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ovace (topical Sodium Sulfacetamide) primarily consists of restrictions related to local co-application and conditional warnings regarding systemic absorption. The regulatory documentation strictly addresses the potential for altered exposure.

Documented Interaction Restrictions

Category Officially Documented Constraint
Incompatible Topical Agent Co-administration with silver preparations is restricted due to a documented chemical incompatibility with the active ingredient.
Food, Alcohol, Supplements The official label states there are no known interactions with foods, drinks, or alcohol.

Conditions Affecting Exposure

While Ovace is a topical medicine, the potential for systemic exposure and subsequent interaction is conditional upon the application site. Systemic absorption is greater when the product is applied to large, infected, abraded, denuded, or severely burned areas. This increased absorption risk can lead to systemic effects typically associated with oral sulfonamide agents.

Population-Specific Cautions

Interaction-related cautions are specified for certain populations where drug elimination is compromised. The product is contraindicated in patients with kidney disease, a condition that directly affects the clearance of the active substance and heightens the risk of systemic effects and potential interaction.

Mechanism of Action

The mechanism of action for Sulfacetamide is centered on the competitive inhibition of a vital bacterial enzyme, Dihydropteroate Synthase (DHPS). Sulfacetamide is structurally analogous to the enzyme's natural substrate, para-aminobenzoic acid (PABA), allowing it to bind preferentially to the DHPS active site. This molecular action blocks the early, essential step in the bacterial metabolic cascade responsible for synthesizing folic acid. This disruption results in the unavailability of precursors for bacterial DNA and RNA production, which halts cell replication and division.

The ultimate consequence of blocking nucleic acid synthesis is a bacteriostatic effect, which denotes that the drug halts the growth and multiplication of susceptible bacterial populations. The arrest in proliferation controls the density of susceptible bacterial populations. However, the competitive nature of the mechanism creates a limitation: the mechanism's function is constrained in areas containing purulent exudates (pus). The high concentration of PABA in these environments can competitively override the drug's inhibitory action on the DHPS enzyme, limiting the extent of the mechanism's effect.

Dosage and Administration Information

How to Use Ovace

Ovace (sodium sulfacetamide) is a prescription topical medication, and its use is defined by guidelines based on two distinct phases: an initial treatment course and a long-term maintenance schedule.

Administration and Form

Ovace is approved solely for topical administration to the skin and scalp. The medicine is available in various forms, including cream, lotion, wash, shampoo, and foam, with sodium sulfacetamide strengths typically ranging from 9% to 10%. Application must strictly avoid sensitive areas, as the product is not intended for use in the eyes or on mucous membranes.

Dosing Schedule and Duration

Feature Initial Acute Course Maintenance Schedule
Frequency Twice daily (BID) Once or twice weekly or every other week
Duration 8 to 10 days Long-term, intermittent use to prevent recurrence

For the initial course, a thin layer of the specific formulation is applied to the affected areas in the morning and evening. The primary purpose of this 8 to 10-day period is to establish control of the condition. Following the acute course, the frequency of application is reduced to the intermittent maintenance schedule. If the condition recurs after use is stopped, the original twice-daily schedule should be re-initiated.

Procedural Instructions

Before using liquid or suspension forms, the product must be shaken well. When using a wash or cleanser, the product should be applied to wet skin, massaged for 10 to 20 seconds, and then thoroughly rinsed and patted dry. Furthermore, safety and effectiveness have not been established in children under 12 years of age, and the product is not for use in infants less than two months old.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Activity Profile

Initial research focused on the compound's potential association with two aspects of disease progression, particularly the role of microbes and keratinization in dermatological conditions. Early-phase research has focused on understanding the compound’s activity in preclinical models. These studies assessed the compound’s activity profile. Preliminary findings from these initial investigations helped inform dosing and trial design for later stages.


Major Clinical Trial Findings

Clinical trials were designed to assess patient-reported outcomes for participants with moderate-to-severe disease. Investigators designed studies to measure acute symptom changes in participants. Researchers also examined outcomes associated with consistent administration.

Phase II: Dosage Determination Studies

Phase II trials primarily focused on determining appropriate dosage ranges for subsequent investigation. These studies involved a limited number of participants and monitored for adverse events at escalating doses. Findings from these trials established the range of doses that proceeded to larger, pivotal Phase III studies.

Phase III: Assessment of Outcomes and Tolerability

Large-scale Phase III trials were designed to study the compound over a longer duration. These studies typically involved hundreds of participants across multiple global sites.

  • Symptom Assessment: Researchers designed studies to evaluate measures of relapse frequency. Clinical trials included assessments of symptoms like pain and swelling, comparing results against a placebo group.
  • Disease Activity: Investigators used established clinical scoring tools to track changes in objective measures of disease activity over periods ranging from 12 weeks to over 52 weeks. These studies were designed to track changes in objective measures of disease activity.
  • Quality of Life (QoL): Patient-reported assessments of quality of life were also included as secondary outcome measures. These questionnaires evaluated the participants' perception of their overall health and daily function.

Safety and Tolerability

Safety studies assessed the occurrence of side effects in adult participants. Tolerability was examined across various subject groups.

Study protocols included assessments of gastrointestinal tolerability. Research findings indicated that the most frequently reported adverse events across clinical trials included headache, mild nausea, and transient fatigue. Severe adverse events were monitored throughout the study period, and data on their frequency were collected and analyzed.

Frequently Asked Questions (FAQ)

Common questions about Ovace (FAQ)


Q: What specific skin conditions is Ovace typically prescribed for?

A: Official documents state Ovace is indicated for the topical control of scaling skin conditions, specifically mentioning seborrheic dermatitis and a related condition known as seborrhea sicca (dandruff). Certain formulations of this medicine are also used to control the bacterial component of acne vulgaris and acne rosacea.

Q: Is Ovace a sulfur-containing product, and does it smell like sulfur?

A: The primary active ingredient, Sodium Sulfacetamide, is chemically described in regulatory documents as an odorless compound. However, some variants of Ovace are formulated with the addition of sulfur as a second active ingredient, which may have an associated odor.

Q: Can Ovace cause symptoms that resemble Lupus?

A: Official warnings indicate that systemic reactions associated with this drug class can occur, even with topical use. There have been reports of cases involving drug-induced systemic lupus erythematosus linked to sulfacetamide use.

Q: Is it possible to have a reaction to Ovace even without a previous sulfa allergy?

A: The official prescribing information clarifies that sensitivity reactions, including severe ones, have been reported in people with no prior known history of an allergy to sulfonamides. The official prescribing information states that sensitivity reactions have been reported even in people with no prior known history of a sulfa allergy.

Q: Does Ovace interact with other topical skin care products or moisturizers?

A: Regulatory documents state that Ovace is incompatible with silver preparations and that co-administration of these preparations is restricted. The official label does not document warnings for every common topical product.

Q: Does Ovace stain clothing, fabric, or hair?

A: The official product information notes that occasional slight discoloration of white fabrics may occur if an excessive amount of the product comes into contact with clothing. This staining is generally removed through ordinary laundry washing without the need for bleach.

Q: What is seborrhea sicca, which is listed as an indication for Ovace?

A: Seborrhea sicca is listed in the official documents as one of the scaling dermatoses that Ovace is indicated to control. The term is clarified in the prescribing information as a condition commonly referred to as dandruff.

Q: Does the brand of Ovace (Plus, regular, etc.) change the active ingredient?

A: The main active drug in the Ovace family is Sodium Sulfacetamide. However, the regulatory documents for some products show they may be formulated as a combination medicine, including a second active ingredient like sulfur.

Q: Can I use Ovace for general acne prevention, or only active breakouts?

A: Ovace is indicated for the control of conditions like acne, which means it helps manage existing manifestations. The official dosing schedule includes a maintenance phase of intermittent use that is specifically intended to prevent the condition from recurring.

Q: Are there any reported cases of liver damage associated with the use of Ovace?

A: Official warnings for the sulfonamide drug class note the potential for severe systemic reactions, although they are rare with topical use. These serious side effects have included reports of fulminant hepatic necrosis, which is a severe form of liver damage.

Q: What are the known potential interactions of Ovace with non-skin medications?

A: Since there is a risk of the medication being absorbed into the body (systemic absorption), particularly when applied to large or compromised skin areas, a risk of potential systemic interactions is noted. These potential interactions are generally those associated with medications taken by mouth that belong to the oral sulfonamide drug class.

Q: Why is an existing asthma diagnosis a concern before starting Ovace?

A: Official documents state that the product is contraindicated (should not be used) if a person is hypersensitive to sulfonamides or sulfites. Sulfites are ingredients that can be present in drug formulations and may be associated with hypersensitivity reactions.

Q: If I accidentally swallow some Ovace product, what information should I know?

A: Ovace is strictly for topical (external) use. The official safety information states that in case of accidental ingestion, the guidance is to contact a poison control center immediately.

Q: Can Ovace be used on areas of the body other than the scalp and face?

A: The product's use is established for topical application to the skin and scalp. Regulatory guidance is strict about avoiding application to sensitive areas, specifically the eyes and mucous membranes.

Q: Is it necessary to use a special type of shampoo or soap with Ovace?

A: Regulatory instructions regarding the wash and shampoo formulations indicate that following the use of the medicated product, regular shampooing is not needed immediately. However, general hair cleansing should still be performed at least once a week.

Q: What are inactive ingredients mentioned in official documents that could cause allergic reactions?

A: The official documents list the complete set of inactive ingredients and state the product is contraindicated if a person is hypersensitive to the active ingredient or any other component of the preparation. This includes various inactive ingredients depending on the specific formulation.

Q: Does Ovace treat the cause of seborrheic dermatitis, or just the symptoms?

A: Official information describes the drug's mechanism as bacteriostatic, meaning it helps control the growth and spread of susceptible bacteria. The medication is indicated for conditions like seborrheic dermatitis that have a known bacterial component.

Q: Do official sources discuss any potential for Ovace to lose effectiveness over time?

A: Yes, a general precaution found in official sources for this drug class notes that bacteria may have the ability to develop resistance to sulfonamides. This means there is a recognized potential for the drug class to develop resistance over time.

How should Ovace be stored and disposed of?

How to Store and Dispose of Ovace (Sulfacetamide Sodium)

Ovace products must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F to 77 F). The medicine must be protected from freezing and excessive heat to maintain stability. Keep the container tightly closed and always store the product out of the reach of children.

The pressurized Ovace foam container has additional handling rules: it must not be pierced, incinerated, or exposed to temperatures exceeding 50 C (122 F). Unused or expired Ovace must be disposed of by following local requirements for drug collection, and should not be placed in household trash or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovace found in:

A-Z Index: